Ezra E W Cohen

7PUBLICATIONS
66CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Pacific Peoples cultural determinants of health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

|Dec 19, 2025
Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs.

Thomas S Hoang, Farhoud Faraji, Amaya N Mendez-Molina

|Nov 13, 2023
Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.

Poorva Vaidya, Ezra E W Cohen

|Mar 31, 2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.

David S Hong, Michael Postow, Bartosz Chmielowski

|Mar 25, 2023
Expert Consensus Statement: Management of Dysphagia in Head and Neck Cancer Patients.

Maggie A Kuhn, M Boyd Gillespie, Stacey L Ishman

|Jun 20, 2020
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.

Glenn J Hanna, Jeffrey P Guenette, Nicole G Chau

Pageof 2